Opinion

Video

Monitoring Strategies for Managing ADC Toxicities in mBC

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.

Video content above has been prompted by the following:

  • Toxicity management is critical for patients on antibody-drug conjugates (ADCs). What are the most important ADC-related AEs that pharmacists should monitor (eg, neutropenia, diarrhea, ILD, mucositis) for T-DXd, SG, and Dato-DXd?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
5 experts in this video
1 expert is featured in this series.
5 experts in this video
5 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Chemotherapy IV drip -- Image credit: sweetlemontea | stock.adobe.com
June 4th 2025

ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

Gillian McGovern, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Antibodies attacking cancer cell | Image Credit: © Anusorn - stock.adobe.com
June 2nd 2025

ASCO 2025: Expert Insights on Endocrine, Cardiac, Ocular, and Dermatologic Toxicities in Breast Cancer Care

Alexandra Gerlach, Associate Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
3D visualization of breast cancer cells | Image Credit: © Jack - stock.adobe.com
May 23rd 2025

APOBEC3 Mutagenesis May Drive Therapy Resistance in Patients With Breast Cancer

Alexandra Gerlach, Associate Editor
Woman with breast cancer awareness pink ribbon on her shirt -- Image credit: Siam | stock.adobe.com
May 21st 2025

Denosumab With Ovarian Function Suppression and Aromatase Inhibitor Therapy in ER-Positive, Early-Stage Breast Cancer

Grace Morrison, PharmD Candidate